204 related articles for article (PubMed ID: 25170636)
21. Serum levels of IL-6, IL-8, and IL-10 are indicators of prognosis in pancreatic cancer.
Feng L; Qi Q; Wang P; Chen H; Chen Z; Meng Z; Liu L
J Int Med Res; 2018 Dec; 46(12):5228-5236. PubMed ID: 30304975
[TBL] [Abstract][Full Text] [Related]
22. [Predictive value of combination detection of tissue Pgp1 expression and preoperative serum CEA level for colorectal cancer].
Wu F; Chen L; Wu W; Jiang B; Su X
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Apr; 20(4):443-449. PubMed ID: 28440527
[TBL] [Abstract][Full Text] [Related]
23. Interleukin-8 level as a prognostic marker in patients with hepatitis B virus-associated hepatocellular carcinoma treated with transarterial chemoembolization.
Kim SS; Cho HJ; Won JH; Bae JI; Kang DR; Lee JD; Shin SJ; Lee KM; Yoo BM; Kim JK; Lee JH; Ahn SJ; Park JH; Cho SW; Cheong JY
Cytokine; 2015 Dec; 76(2):449-457. PubMed ID: 26163999
[TBL] [Abstract][Full Text] [Related]
24. Low serum interleukin-6 levels as a predictive marker of recurrence in patients with hepatitis B virus related hepatocellular carcinoma who underwent curative treatment.
Cho HJ; Kim SS; Ahn SJ; Park SY; Park JH; Kim JK; Wang HJ; Cheong JY; Cho SW
Cytokine; 2015 Jun; 73(2):245-52. PubMed ID: 25797190
[TBL] [Abstract][Full Text] [Related]
25. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.
Dijkgraaf EM; Santegoets SJ; Reyners AK; Goedemans R; Wouters MC; Kenter GG; van Erkel AR; van Poelgeest MI; Nijman HW; van der Hoeven JJ; Welters MJ; van der Burg SH; Kroep JR
Ann Oncol; 2015 Oct; 26(10):2141-9. PubMed ID: 26216383
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of interleukin-6 and interleukin-8 in laryngeal squamous cell cancer.
Hao W; Zhu Y; Zhou H
Med Oncol; 2013 Mar; 30(1):333. PubMed ID: 23269580
[TBL] [Abstract][Full Text] [Related]
27. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
[TBL] [Abstract][Full Text] [Related]
28. Combination of IL-6, IL-10, and MCP-1 with traditional serum tumor markers in lung cancer diagnosis and prognosis.
Pan YW; Zhou ZG; Wang M; Dong JQ; Du KP; Li S; Liu YL; Lv PJ; Gao JB
Genet Mol Res; 2016 Nov; 15(4):. PubMed ID: 27819723
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma.
Qian F; Yang W; Wang R; Xu J; Wang S; Zhang Y; Jin B; Yu K; Han B
J Thorac Cardiovasc Surg; 2018 Mar; 155(3):1227-1235.e2. PubMed ID: 29223834
[TBL] [Abstract][Full Text] [Related]
30. Serum biomarkers for predicting overall survival and early mortality in older patients with metastatic solid tumors.
Kim SH; Kim JW; Hwang IG; Jang JS; Hong S; Kim TY; Baek JY; Shin SH; Sun S; Hong DS; Kim HJ; Hong YS; Woo IS; Lee JH; Kim JH
J Geriatr Oncol; 2019 Sep; 10(5):749-756. PubMed ID: 30952517
[TBL] [Abstract][Full Text] [Related]
31. Elevated IL-8, TNF-α, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival.
Sharma J; Gray KP; Harshman LC; Evan C; Nakabayashi M; Fichorova R; Rider J; Mucci L; Kantoff PW; Sweeney CJ
Prostate; 2014 Jun; 74(8):820-8. PubMed ID: 24668612
[TBL] [Abstract][Full Text] [Related]
32. Cytokines in bronchoalveolar lavage fluid and serum of lung cancer patients during radiotherapy - Association of interleukin-8 and VEGF with survival.
Crohns M; Saarelainen S; Laine S; Poussa T; Alho H; Kellokumpu-Lehtinen P
Cytokine; 2010 Apr; 50(1):30-6. PubMed ID: 20044268
[TBL] [Abstract][Full Text] [Related]
33. Circulating Inflammation Markers, Risk of Lung Cancer, and Utility for Risk Stratification.
Shiels MS; Katki HA; Hildesheim A; Pfeiffer RM; Engels EA; Williams M; Kemp TJ; Caporaso NE; Pinto LA; Chaturvedi AK
J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26220734
[TBL] [Abstract][Full Text] [Related]
34. Elevated serum YKL-40, IL-6, CRP, CEA, and CA19-9 combined as a prognostic biomarker panel after resection of colorectal liver metastases.
Peltonen R; Gramkow MH; Dehlendorff C; Osterlund PJ; Johansen JS; Isoniemi H
PLoS One; 2020; 15(8):e0236569. PubMed ID: 32756596
[TBL] [Abstract][Full Text] [Related]
35. Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma.
Matsuo K; Hasegawa K; Yoshino K; Murakami R; Hisamatsu T; Stone RL; Previs RA; Hansen JM; Ikeda Y; Miyara A; Hiramatsu K; Enomoto T; Fujiwara K; Matsumura N; Konishi I; Roman LD; Gabra H; Fotopoulou C; Sood AK
Eur J Cancer; 2015 Sep; 51(14):1978-88. PubMed ID: 26238017
[TBL] [Abstract][Full Text] [Related]
36. Prognostic impact of serum albumin levels on the recurrence of stage I non-small cell lung cancer.
Jin Y; Zhao L; Peng F
Clinics (Sao Paulo); 2013 May; 68(5):686-93. PubMed ID: 23778417
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy.
Koch A; Fohlin H; Sörenson S
J Thorac Oncol; 2009 Mar; 4(3):326-32. PubMed ID: 19155996
[TBL] [Abstract][Full Text] [Related]
38. Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer.
Hu LA; Fu Y; Zhang DN; Zhang J
Asian Pac J Cancer Prev; 2013; 14(4):2563-6. PubMed ID: 23725175
[TBL] [Abstract][Full Text] [Related]
39. Association of interleukin-6 and tumor necrosis factor-α with mortality in hospitalized patients with cancer.
Stoll JR; Vaidya TS; Mori S; Dusza SW; Lacouture ME; Markova A
J Am Acad Dermatol; 2021 Feb; 84(2):273-282. PubMed ID: 32171811
[TBL] [Abstract][Full Text] [Related]
40. IL-6 and IL-8 cytokines are associated with elevated prostate-specific antigen levels among patients with adenocarcinoma of the prostate at the Uganda Cancer Institute.
Katongole P; Sande OJ; Nabweyambo S; Joloba M; Kajumbula H; Kalungi S; Reynolds SJ; Ssebambulidde K; Atuheirwe M; Orem J; Niyonzima N
Future Oncol; 2022 Feb; 18(6):661-667. PubMed ID: 34881637
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
